



BILFINGER

Press Release

February 7, 2019

Bilfinger Delivers a Pharmaceutical Production Plant to Russia

Bilfinger Industrietechnik Salzburg, a subsidiary of the Bilfinger Group, has been awarded a contract by the Russian pharma company NovaMedica for the design and construction of three solution-preparation lines for the production of sterile, pharmaceutical dosage forms. This is the first contract Bilfinger Industrietechnik Salzburg has secured in Russia. The production facility to be constructed will turn out chemical and biochemical products, emulsions, and cytostatic agents under aseptic conditions.

Duncan Hall, Bilfinger's Chief Operating Officer: "For us, Russia is a market of strategic interest. The production of pharmaceuticals increasingly is being localized as part of the Russian government's 'Pharma 2030' strategy. This creates demand for high-end pharmaceutical production facilities, which is precisely what we have on offer in our engineering portfolio."

The scope of delivery will include 15 mixing and buffer tanks with a capacity of up to 1,000 liters, as well as several isolators. Bilfinger will be responsible for the engineering, mechanical and electrical fabrication, automation and re-assembly work, as well as for on-site commissioning and acceptance testing (SAT). The fully automated production plant will be planned and built on the basis of an aseptic design and will meet the cGMP standards as well as the strictest international and Russian standards of quality. It will be controlled by means of a modern software system. The construction project is to be completed in 2020 and the first medicinal products are scheduled to be greenlit for industrial production in 2023.

The production plant will be installed in a newly built pharmaceutical complex within the Vorsino industrial park in the Kaluga region, 190 km southwest of Moscow.

The Russian pharmaceuticals firm NovaMedica was founded in 2012 by Domain Associates LLC, a leading US venture capital firm, together with RUSNANO, JSC. The company's mission is to acquire intellectual property rights for innovative pharmaceutical products and technologies for the Russian market, to develop and implement its own R&D projects, and to build modern and GMP-compliant pharmaceutical production facilities.

Bilfinger Industrietechnik Salzburg specializes in the development and construction of process plants for the pharma and biopharma industry. Its range of products encompasses bioreactors



BILFINGER

and fermentation systems, as well as systems for the preparation and purification of solutions, downstream skids, CIP/SIP systems and water generation plants.

Bilfinger is a leading international industrial services provider. The Group enhances the efficiency of assets, ensures a high level of availability and reduces maintenance costs. The portfolio covers the entire value chain from consulting, engineering, manufacturing, assembly, maintenance, plant expansion as well as turnarounds and also includes environmental technologies and digital applications.

The company delivers its services in two business segments: Engineering and Technologies and Maintenance, Modifications & Operations. Bilfinger is primarily active in the regions Continental Europe, Northwest Europe, North America and the Middle East. Process industry customers come from sectors that include chemicals & petrochem, energy & utilities, oil & gas, pharma & biopharma, metallurgy and cement. With its 36,000 employees, Bilfinger upholds the highest standards of safety and quality and generated revenue of €4.044 billion in financial year 2017.

You can find additional information, photographs and videos at

